Company news
Avacta Group Plc (LSE:AVCT) news
Every Avacta Group Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Aberforth Geared Value & Income Trust Plc - Final Results
July 30, 2026
Avacta : Accelerated Amortized Payment of Convertible Bond Installment
July 9, 2026
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
July 8, 2026
Avacta : Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer
June 25, 2026
Year-to-date business update ahead of AGM
June 22, 2026
Oversubscribed Strategic Equity Fundraise of £9m
June 5, 2026
Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
June 1, 2026
Avacta : Annual Report and Accounts for the year ending 31 December 2025
May 29, 2026
Unaudited Preliminary Full Year 2025 Results
May 19, 2026
Notice of Preliminary Results and Presentation
May 13, 2026
Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
May 6, 2026
Avacta data AACR underline AVA6103 profile
April 21, 2026
Christina Coughlin - In Vivo 2026 Rising Leader
April 14, 2026
Q1 2026 Business Update
April 9, 2026
Avacta Announces Science Day 2026
April 8, 2026
First patient treated in Phase 1 trial of AVA6103
March 31, 2026
Result of Oversubscribed Fundraise
March 27, 2026
Proposed Fundraise to raise approximately £10m
March 26, 2026
Issue of Equity
March 26, 2026
Presentations of pre|CISION® Platform Candidates
March 17, 2026
Phase 1 study opening for AVA6103
March 16, 2026
PreCISION payload delivery advantage over ADC
February 24, 2026
Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven An...
February 24, 2026
Avacta to Participate in Conference March 2026
February 18, 2026
Appointment of CSO
February 9, 2026
Avacta appoints Francis Wilson as Chief Scientific Officer
February 9, 2026
Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program
February 3, 2026
Faridoxorubicin Program Clinical Updates
February 3, 2026
Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION®...
January 21, 2026
FDA Clearance of IND Application for AVA6103
January 21, 2026
Year-end trading update
January 20, 2026
Avacta Announces Year-end Trading Update
January 20, 2026
Appointment of Nominated Adviser & TVR
January 20, 2026
Avacta reports new AVA6103 pharmacology data
December 18, 2025
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers
December 17, 2025
Faridoxorubicin Phase 1b SGC data
December 17, 2025
Preliminary Data in Faridoxorubicin Phase 1b Trial
December 8, 2025
Completion of Placing and TVR
November 3, 2025
Block Listing Six Monthly Return
October 27, 2025
Avacta presents preclinical data at AACR-NCI-EORTC
October 27, 2025
Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Mol...
October 25, 2025
Notice of Investor Presentation
October 23, 2025
Equity fundraise of £16 million
October 20, 2025
Avacta Presents Phase 1a Data for Faridoxorubicin
October 20, 2025
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical...
October 19, 2025
Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets ...
October 13, 2025
Avacta to present data at EORTC-NCI-AACR
October 13, 2025
Interim Half Year Results 2025
September 30, 2025
Notice of Interim Results
September 15, 2025
Shortlisted for AIM Awards Technology of the Year
September 9, 2025